| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Cyclopenthiazide adverse reaction |
Causative agent (attribute) |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Allergy to cyclopenthiazide (finding) |
Causative agent (attribute) |
False |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
|
| Product containing cyclopenthiazide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely cyclopenthiazide 500 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
|
| Amiloride hydrochloride 2.5 mg and cyclopenthiazide 250 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
|
| Amiloride hydrochloride+cyclopenthiazide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
|
| Oxprenolol+cyclopenthiazide 160mg/250mcg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
|
| Product containing cyclopenthiazide and oxprenolol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
2 |
| Product containing amiloride and cyclopenthiazide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
2 |
| Allergy to cyclopenthiazide (finding) |
Causative agent (attribute) |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Amiloride hydrochloride 2.5 mg and cyclopenthiazide 250 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Amiloride hydrochloride 2.5 mg and cyclopenthiazide 250 microgram oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely cyclopenthiazide 500 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely cyclopenthiazide 500 microgram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Cyclopenthiazide- and oxprenolol-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
2 |
| Amiloride hydrochloride 2.5 mg and cyclopenthiazide 250 microgram oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Amiloride- and cyclopenthiazide-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely cyclopenthiazide 500 microgram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Product containing cyclopenthiazide in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Product containing only amiloride and cyclopenthiazide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
2 |
| Cyclopenthiazide only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Product containing only cyclopenthiazide and oxprenolol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
2 |
| Product containing only amiloride and cyclopenthiazide in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
2 |
| Product containing only cyclopenthiazide and oxprenolol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
2 |
| Product containing only cyclopenthiazide in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
1 |
| Amiloride hydrochloride 2.5 mg and cyclopenthiazide 250 microgram oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
2 |
| Amiloride hydrochloride 2.5 mg and cyclopenthiazide 250 microgram oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Cyclopenthiazide (substance) |
Inferred relationship |
Some |
2 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]